Catalyst
Slingshot members are tracking this event:
Inovio Pharma (INO) to complete Phase 1/2a study of INO-3112 DNA vaccine in subjects with HPV associated head and neck squamous cell cancer in early 2018
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| INO |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 07, 2018
Occurred Source:
https://clinicaltrials.gov/ct2/show/NCT02163057?term=inovio+pharmaceuticals&recr=Open&rank=3&submit_fld_opt=
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Head & Neck Cancer, Hpv, Ino-3112, Dna-based Immunotherapy, Phase 1/2 Study
